Q-omics provides the consensus-scored FAM83H profile across patient tissues and cancer cell-line models. FAM83H expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM83H is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FAM83H RNA expression shows 19,354 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where FAM83H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM83H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM83H survival associations across molecular data types. FAM83H RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM83H RNA expression–survival associations across cancer types. High FAM83H expression shows unfavorable associations in ACC, SKCM, LIHC, UVM, PAAD and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM83H RNA expression.
This table summarizes FAM83H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM83H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM83H shows higher tumor expression in HNSC, COAD, STAD, LIHC, LUAD and BLCA. The HNSC box plot shows higher FAM83H RNA expression in tumor versus normal tissue (log2 FC = +1.633, t-test p < 0.001).
This table shows molecular features associated with FAM83H in patient tissues and cancer cell lines. In patient samples, FAM83H shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM83H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
